Skip to main content

Table 4 Modification of clinical score and respiratory function tests after gentamicin treatment.

From: In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

 

Group A

n = 9

Group B

n = 4

Group C

n = 5

 

D0

D15

p

D0

D15

p

D0

D15

p

CFCS

30(8)

21(8)

0.007

25(1)

22 (1)

NS

23.5(2)

23(3)

NS

FEV1(L)

1.82(0.8)

2.07(0.8)

0.04

1.68(0.4)

1.77(0.3)

NS

2(0.3)

2.12(0.4)

NS

FVC(L)

2.2(1)

2.36(0.9)

NS

2.08(0.6)

2.14(0.5)

NS

2.93(0.5)

3(0.4)

NS

FEF25–75(L)

1.54(1.1)

1.95(1.06)

NS

1.91(0.9)

1.96(0.8)

NS

1.93(1.8)

1.99(1.8)

NS

  1. Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. CFCS refers to the Cystic Fibrosis Clinical Score. FEV1, FVC, FEF25–75 as defined in Table 2 and are expressed as absolute values. Data are described as mean (SD). Comparison with Wilcoxon test.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us